Working together against deadly Marburg virus

PIKADO BV is proud to have contributed to the successful proposal MARVAX: this international research consortium receives highly endowed Horizon Europe funding for the development of vaccines against Marburg viruses.

The multidisciplinary European consortium MARVAX will receive 7.4 million euros over the next four years for the research and development of vaccines against Marburg viruses. Researchers from France, Spain and Germany will develop novel vaccine candidates, which will be tested in preclinical animal models and bring them to the stage where they are ready for phase I clinical trials. The Bernhard Nocht Institute for Tropical Medicine (BNITM, Germany) will coordinate the MARVAX consortium that also includes the Institut Pasteur (France), the National Centre for Biotechnology of the Spanish National Research Council (CNB-CSIC, Spain), and CZ Vaccines (Zendal group, Spain).

See the full Press Release here: https://www.bnitm.de/en/news/news/working-together-against-deadly-marburg-virus

PIKADO BV will support the coordinator for the scientific management of MARVAX.